Abstract Number: 0530 • ACR Convergence 2022
Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)
Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA),…Abstract Number: 0530 • ACR Convergence 2021
Dysregulation of IGFI/IGF1R Pathway and IGF1R+3179A/G Polymorphism in Pathogenesis of Sjögren’s Syndrome
Background/Purpose: Sjӧgren’s syndrome (SS) is an autoimmune exocrinopathy characterized by chronic salivary and lacrimal gland dysfunction. Alterations of Insulin-like growth factor (IGF) pathway has been…Abstract Number: 0530 • ACR Convergence 2020
Pediatric APS: Clinical Features, Therapeutic Interventions, and Damage in a Series of 22 Cases
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…
Search by Abstract Number Results
Didn't find what you were looking for? Try the Advanced Search »